Reported Sunday, Bristol Myers Squibb's Phase 3 SCOUT-HCM Trial Of Camzyos Meets Primary Endpoint In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28Results demonstrate the potential for



























